Vis enkel innførsel

dc.contributor.authorStene, Guro Birgitte
dc.contributor.authorBalstad, Trude Rakel
dc.contributor.authorLeer, Anne Silja Mäkitalo
dc.contributor.authorBye, Asta
dc.contributor.authorKaasa, Stein
dc.contributor.authorFallon, Marie T.
dc.contributor.authorLaird, Barry J
dc.contributor.authorMaddocks, Matthew
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.identifier.citationCancers. 2019, 11 (1925), .nb_NO
dc.description.abstractBackground: Muscle mass and physical function (PF) are common co-primary endpoints in cancer cachexia trials, but there is a lack of data on how these outcomes interact over time. The aim of this secondary analysis of data from a trial investigating multimodal intervention for cancer cachexia ( NCT01419145) is to explore whether changes in muscle mass and PF are associated with weight loss and cachexia status at baseline. Methods: Secondary analysis was conducted using data from a phase II randomized controlled trial including 46 patients with stage III–IV non-small cell lung cancer (n = 26) or inoperable pancreatic cancer (n = 20) due to commence chemotherapy. Cachexia status at baseline was classified according to international consensus. Muscle mass (assessed using computed tomography (CT)) and PF outcomes, i.e., Karnofsky performance status (KPS), self-reported PF (self-PF), handgrip strength (HGS), 6-minute walk test (6MWT), and physical activity (PA), were measured at baseline and after six weeks. Results: When compared according to cachexia status at baseline, patients with no/pre-cachexia had a mean loss of muscle mass (−5.3 cm2, p = 0.020) but no statistically significant change in PF outcomes. Patients with cachexia also lost muscle mass but to a lesser extent (−2.8 cm2, p = 0.146), but demonstrated a statistically significant decline in PF; KPS (−3.8 points, p = 0.030), self-PF (−8.8 points, p = 0.027), and HGS (−2.7 kg, p = 0.026). Conclusions: Weight loss history and cachexia status at baseline are of importance if one aims to detect changes in PF outcomes in cancer cachexia trials. To improve the use of co-primary endpoints that include PF in future trials, outcomes that have the potential to detect change relative to weight loss should be investigated further.nb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleDeterioration in Muscle Mass and Physical Function Differs According to Weight loss History in Cancer Cachexianb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.localcode© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
cristin.unitnameInstitutt for nevromedisin og bevegelsesvitenskap
cristin.unitnameInstitutt for klinisk og molekylær medisin

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal